Global Innovative Platforms Inc.

Global Innovative Platforms Inc. is a U.S.-based development-stage company focused on breath analysis and air-quality technologies for animal health and related diagnostics. Its core platform technologies, VOCAM Plus and FROG, combine gas chromatography and AI software to detect disease markers, assess treatment effectiveness, and identify potentially toxic environmental or food conditions.

17.17

17.17

— Global Innovative Platforms Inc.
%
Diagnostic technology platforms60% Core breath and air analysis systems used to detect biomarkers and assess health conditions.
Technology licensing25% Licensing arrangements that monetize proprietary technology and know-how.
Research and development services15% Internal and collaborative development work to expand applications and improve product readiness.

The company appears to sell primarily into animal health and adjacent diagnostic use cases, with a focus on buyers that...

  • Animal health partnersprimary

    Veterinary and animal-health organizations that would use breath-analysis tools to detect disease or monitor treatment effectiveness.

  • Licensing counterpartiesprimary

    Third parties that license the company's technology and know-how to commercialize products or applications.

  • Research and collaboration partnerssecondary

    Organizations that fund or co-develop applications for VOC detection and related diagnostics.

  • Environmental and food-safety usersemerging

    Potential end users of air-analysis tools for toxic environmental or food-condition detection.

The company is headquartered in the United States and reports in U.S. dollars under U.S. GAAP...

  • •Headquartered in the United States
  • •Reports in U.S. dollars under U.S. GAAP
  • •No disclosed country-level revenue split in the excerpts
  • •Early-stage commercialization limits geographic diversification
  • •Future growth likely depends on U.S. funding and partnerships

Management is focused on securing capital, advancing product development, and moving the breath-analysis platform...

01
Secure additional financingshort-term

The company has limited operating cash generation and needs external funding to continue development.

02
Commercialize breath-analysis technologymedium-term

Revenue depends on turning VOCAM Plus and FROG into market-ready products or licensed solutions.

03
Pursue strategic transaction opportunitiesmedium-term

Management has indicated a plan to merge with an entity that brings experienced management and growth opportunities.

The company is a development-stage business with substantial going-concern risk, limited revenue, and dependence on...

critical

Going-concern and liquidity risk

Auditors noted substantial doubt about the company's ability to continue as a going concern, and operations depend on new capital.

Scope
Ongoing operating losses and limited revenue
Materiality
high
high

Dependence on licensed intellectual property

The business relies on Defiant Technologies' VOCAM Plus license, and expired patents may allow competitors to replicate the technology.

Scope
VOCAM Plus commercialization
Materiality
high
high

Financing dilution

Future funding is expected to come from equity or convertible instruments, which can dilute existing shareholders.

Scope
Capital raises and strategic transactions
Materiality
high
high

Commercialization and adoption risk

The company has limited revenue and no approved products for sale, so demand and regulatory progress remain uncertain.

Scope
Animal-health diagnostics and licensing
Materiality
high
medium

Competitive disadvantage

Management discloses limited financial and personnel resources versus established competitors.

Scope
Product development and commercialization
Materiality
medium
Revenue recognition for licensing arrangements
Can create quarter-to-quarter volatility in reported revenue
Research and development expense recognition
Suppresses near-term earnings and reflects product-readiness risk
Long-lived asset and intangible impairment
Could cause non-cash charges if expected commercialization weakens
Going-concern and financing disclosures
Important for assessing solvency, dilution, and survival risk

Global Gas Corp

HGAS · Industrial Inorganic Chemicals

HARVARD BIOSCIENCE INC

HBIO · Laboratory Analytical Instruments

Co-Diagnostics, Inc.

CODX · Surgical & Medical Instruments & Apparatus

GLOBAL TECHNOLOGIES LTD

GTLL · Radio & Tv Broadcasting & Communications Equipment

INTELLIGENT BIO SOLUTIONS INC.

INBS · Surgical & Medical Instruments & Apparatus

Greenland Mines Ltd

GRML · Biological Products, (No Diagnostic Substances)

: 28/04/2026